This concept captures the distinction between immunologic cross-reactivity and clinically meaningful coallergy between peanut and soy. The review treats this as a central interpretive issue.
First-pass extracted concept
Peanut-soy cross-reactivity
Candidate: concept label1 source documents7 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
What the tool is doing
What problem it solves
What it does not solve
Evidence Snippets
Supporting Sources
Linked Claims
Elimination of all legumes in individuals with clinical reactions to one legume is generally unwarranted despite frequent multiple positive legume tests.
Molecular studies indicate that peanut and soy contain both homologous and unique allergenic proteins, helping explain why serologic cross-reactivity does not always produce clinical coallergy.
Peanut allergy is commonly severe and can cause multisystem reactions, anaphylaxis, hospitalization, and fatal reactions.
Peanut allergy may resolve in some infants, but once established in early childhood it rarely remits.
Serologic or skin-test cross-reactivity between peanut and soy is common, but clinically important peanut-soy coallergy is uncommon.
Soy allergy is generally less common than peanut allergy and is usually a transient allergy of infancy or childhood.
The reported Swedish severe soy reactions in peanut-allergic individuals raise concern but remain limited by uncertainty about assay specificity and possible occult peanut exposure.